Tyra Biosciences

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Saint,Petersburg,,Russia,-,29,March,2020:,Northrop,Grumman,Business

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

CELC

NESR

SITC

TYRA

USAR

Northrop Grumman Posts Downbeat Results, Joins Halliburton And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

CalixSan,Jose,,Ca,,Usa,-,Feb,26,,2020:,Calix,Headquarters.

ADPT

CALX

GELS

GURE

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

INMB

MKDW

MULN

SHF Holdings, Inc. - Class A Common Stock

SHFS

SLSR

SUNE

TNMG

Why Calix Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket

Movimiento de acciones

ALTG

Mobile Infrastructure Corporation Common Stock

BEEP

CRML

CULP

GBTG

GMHS

KIDZ

STSS

THTX

WAFD

Why WaFd Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket

Tyra Biosciences Inc

TYRANNA RESOURCES LTD by Tyranna Resources Ltd.

Tyranna Resources Ltd

Press Releases

Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

Earnings

Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights

Tyra Biosciences to Present at Upcoming Investor Conferences

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium

Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors

Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights

Abivax

Akebia Therapeutics

AnaptysBio

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

Cogent Biosciences

Immatics

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

Keros Therapeutics

Kura Oncology

MeiraGTx Hldgs

Organogenesis Holdings

Precigen

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Regenxbio

Relay Therapeutics

Sage Therapeutics

Sionna Therapeutics

Stoke Therapeutics

Savara

Tourmaline Bio

Upstream Bio

Valneva

Verve Therapeutics

HC Wainwright & Co.

Wedbush

B of A Securities

Oppenheimer

Comments

Tyra Biosciences

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell